231 related articles for article (PubMed ID: 35752566)
1. Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
Bajaj HS; Chu L; Bansal N; Brown RE; Dhillon G; Gupta R; Bhela JS; Padda JK; Khandwala H; Venn K; Aronson R
Can J Diabetes; 2022 Jul; 46(5):495-502. PubMed ID: 35752566
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.
Blonde L; Bailey TS; Chao J; Dex TA; Frias JP; Meneghini LF; Roberts M; Aroda VR
Adv Ther; 2019 Sep; 36(9):2310-2326. PubMed ID: 31359368
[TBL] [Abstract][Full Text] [Related]
3. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
Aroda VR; Rosenstock J; Wysham C; Unger J; Bellido D; González-Gálvez G; Takami A; Guo H; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Care; 2016 Nov; 39(11):1972-1980. PubMed ID: 27650977
[TBL] [Abstract][Full Text] [Related]
5. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
[No Abstract] [Full Text] [Related]
6. Post hoc efficacy and safety analysis of insulin glargine/lixisenatide fixed- ratio combination in North American patients compared with the rest of world.
Dailey G; Bajaj HS; Dex T; Groleau M; Stager W; Vinik A
BMJ Open Diabetes Res Care; 2019; 7(1):e000581. PubMed ID: 31114694
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan-O-AP randomized controlled trial.
Yang W; Dong X; Li Q; Cheng Z; Yuan G; Liu M; Xiao J; Gu S; Niemoeller E; Chen L; Ping L; Souhami E;
Diabetes Obes Metab; 2022 Aug; 24(8):1522-1533. PubMed ID: 35441412
[TBL] [Abstract][Full Text] [Related]
8. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents.
Skolnik N; Dupree RS; Johnson EL
Curr Med Res Opin; 2017 Dec; 33(12):2187-2194. PubMed ID: 28741967
[TBL] [Abstract][Full Text] [Related]
9. Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J; Handelsman Y; Vidal J; Ampudia Blasco FJ; Giorgino F; Liu M; Perfetti R; Meier JJ
Diabetes Obes Metab; 2018 Dec; 20(12):2821-2829. PubMed ID: 29974618
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial.
Kaneto H; Takami A; Spranger R; Amano A; Watanabe D; Niemoeller E
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():3-13. PubMed ID: 32072742
[TBL] [Abstract][Full Text] [Related]
11. More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L.
Frias J; Puig Domingo M; Meneghini L; Napoli R; Liu M; Soltes Rak E; Aroda VR
Diabetes Obes Metab; 2018 Sep; 20(9):2314-2318. PubMed ID: 29785837
[TBL] [Abstract][Full Text] [Related]
12. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
Goldman J; Trujillo JM
Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.
Davies MJ; Leiter LA; Guerci B; Grunberger G; Ampudia-Blasco FJ; Yu C; Stager W; Niemoeller E; Souhami E; Rosenstock J
Diabetes Obes Metab; 2017 Dec; 19(12):1798-1804. PubMed ID: 28432746
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Efficacy and Safety of Commercially Available Fixed-Ratio Combinations of Insulin Degludec/Liraglutide and Insulin Glargine/Lixisenatide: A Network Meta-analysis.
Visolyi GÁ; Domján BA; Svébis MM; Péterfi A; Lovász BD; Mészáros S; Horváth VJ; Tabák ÁG
Can J Diabetes; 2023 Jun; 47(4):368-377. PubMed ID: 36963632
[TBL] [Abstract][Full Text] [Related]
16. Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes.
Schmider W; Belder R; Lee M; Niemoeller E; Souhami E; Frias JP
Curr Med Res Opin; 2019 Jun; 35(6):1081-1089. PubMed ID: 30550345
[TBL] [Abstract][Full Text] [Related]
17. iGlarLixi provides a higher derived time-in-range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis.
Guo X; Yang W; Zhang J; Dong X; Liu M; Gu S; Lauand F; Li L; Huang Q; Kang L; Souhami E
Diabetes Obes Metab; 2023 Jul; 25(7):2005-2011. PubMed ID: 36999231
[TBL] [Abstract][Full Text] [Related]
18. Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial.
Wysham C; Bonadonna RC; Aroda VR; Puig Domingo M; Kapitza C; Stager W; Yu C; Niemoeller E; Souhami E; Bergenstal RM;
Diabetes Obes Metab; 2017 Oct; 19(10):1408-1415. PubMed ID: 28386990
[TBL] [Abstract][Full Text] [Related]
19. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan-L-CN randomized controlled trial.
Yuan X; Guo X; Zhang J; Dong X; Lu Y; Pang W; Gu S; Niemoeller E; Ping L; Nian G; Souhami E;
Diabetes Obes Metab; 2022 Nov; 24(11):2182-2191. PubMed ID: 35762489
[TBL] [Abstract][Full Text] [Related]
20. Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Yang W; Guo X; Lauand F; Li L; Fang H; Du Q; Kang L
Diabetes Obes Metab; 2024 Apr; 26(4):1197-1206. PubMed ID: 38172083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]